Defective Genome Instability Suppressing Genes May Cause Some Types of Cancer
|
By LabMedica International staff writers Posted on 28 Apr 2016 |
|
Image: Drop-inoculation of Saccharomyces cerevisiae mutants on an agar plate. The assay compares the viability of different yeast mutants (Photo courtesy of Wikimedia Commons).
Cancer researchers reported in a recent study that defects in the expression of genes that suppress gross chromosomal rearrangements (GCRs) were linked to more than 93% of the ovarian and 66% of the colorectal cancer cases they had examined.
Investigators at the University of California, San Diego (USA) worked with the yeast Saccharomyces cerevisiae to identify genome instability suppressing (GIS) genes that acted to prevent chromosomal rearrangements. They reported in the April 13, 2016, online edition of the journal Nature Communications that by using this platform they had been able to identify182 GIS genes that suppressed GCR formation. Another 438 cooperatively acting GIS genes (cGIS) were identified that were not GIS genes, but suppressed the increased genome instability caused by individual query mutations.
Analysis of data derived from The Cancer Genome Atlas (TCGA) allowed the investigators to predict which human genes were associated with GIS pathways. This analysis revealed that a minimum of 93% of ovarian and 66% of colorectal cancer cases had defects affecting one or more predicted GIS gene. These defects included loss-of-function mutations, copy-number changes associated with reduced expression, and silencing. In contrast, acute myeloid leukemia cases did not appear to have defects affecting the predicted GIS genes.
"Mutated GIS genes have long been suspected of playing a role in the development of many types of cancers, but identifying them has been difficult due in large part to a lack of comprehensive GCR tests, or assays, in mammalian systems," said first author Dr. Christopher Putnam, adjunct assistant professor of medicine at the University of California, San Diego School of Medicine. "Before our experiment, only a few dozen cGIS genes were known. Now we know of hundreds. Understanding this process allows us to think more about how carcinogenesis proceeds and it might give us insights into defects that could be therapeutically actionable in the future."
Related Links:
University of California, San Diego
Investigators at the University of California, San Diego (USA) worked with the yeast Saccharomyces cerevisiae to identify genome instability suppressing (GIS) genes that acted to prevent chromosomal rearrangements. They reported in the April 13, 2016, online edition of the journal Nature Communications that by using this platform they had been able to identify182 GIS genes that suppressed GCR formation. Another 438 cooperatively acting GIS genes (cGIS) were identified that were not GIS genes, but suppressed the increased genome instability caused by individual query mutations.
Analysis of data derived from The Cancer Genome Atlas (TCGA) allowed the investigators to predict which human genes were associated with GIS pathways. This analysis revealed that a minimum of 93% of ovarian and 66% of colorectal cancer cases had defects affecting one or more predicted GIS gene. These defects included loss-of-function mutations, copy-number changes associated with reduced expression, and silencing. In contrast, acute myeloid leukemia cases did not appear to have defects affecting the predicted GIS genes.
"Mutated GIS genes have long been suspected of playing a role in the development of many types of cancers, but identifying them has been difficult due in large part to a lack of comprehensive GCR tests, or assays, in mammalian systems," said first author Dr. Christopher Putnam, adjunct assistant professor of medicine at the University of California, San Diego School of Medicine. "Before our experiment, only a few dozen cGIS genes were known. Now we know of hundreds. Understanding this process allows us to think more about how carcinogenesis proceeds and it might give us insights into defects that could be therapeutically actionable in the future."
Related Links:
University of California, San Diego
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Automated Urinalysis Solution
UN-9000
New
Urine Analyzer
respons® UDS100
Latest BioResearch News
- Study Identifies Distinct Immune Signatures to Early Depression and Psychosis
- Genetic Mutation Behind Aggressive Adult Leukemia Offers Treatment Clues
- Disease Gene Discovery Advances Diagnosis of Rare Movement Disorders
- Genetic Discovery Could Improve Diagnosis of Drug-Resistant Epilepsy
- Genetic Discovery May Improve Diagnosis of Rare Dementia Subtype
- Mass Spectrometry Technique Detects Protein and Sugar Changes in Neurodegeneration
- Barcoded DNA Sheds Light on Hidden Complexities in Breast Cancer Detection
- CRISPR-Based Platform Pinpoints Drivers of Acute Myeloid Leukemia in Patient Cells
- Protective Brain Protein Emerges as Biomarker Target in Alzheimer’s Disease
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
Channels
Clinical Chemistry
view channel
Blood-Based Screening Test Targets Early Detection of Colorectal Cancer
Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide, with more than 60% of cases still diagnosed at a late stage. Uptake of existing screening tools remains suboptimal,... Read more
Automated NfL Assay Supports Monitoring of Neurological Disorders
Neuroaxonal injury occurs across a wide range of neurological disorders and remains difficult to monitor noninvasively over time. Blood-based measurement of neurofilament light chain (NfL) provides a biologically... Read more
Molecular Diagnostics
view channel
Plasma ctDNA Testing Predicts Breast Cancer Recurrence After Neoadjuvant Therapy
Accurate identification of breast cancer patients at risk of relapse after pre-surgery treatment is central to guiding adjuvant decisions, particularly in aggressive disease. Circulating fragments of tumor... Read more
New Respiratory Panel Expands Pathogen Detection to 25 Targets
Respiratory infections often present with overlapping symptoms, complicating differential diagnosis in acute and community settings. The stakes are higher for older adults, young children, and people with... Read more
Hematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Immunology
view channel
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read more
Microfluidic Chip Detects Cancer Recurrence from Immune Response Signals
Early identification of treatment response and relapse remains a major challenge in solid tumors, where minimal residual disease is difficult to detect with routine imaging and blood tests.... Read more
Microbiology
view channel
Breath Analysis Approach Offers Rapid Detection of Bacterial Infection
Accurate and rapid identification of bacterial infections remains challenging in acute care, where delays can hinder timely, targeted therapy. Infectious diseases are a major cause of mortality worldwide,... Read more
Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
Direct-to-consumer gut microbiome kits promise personalized insights by profiling fecal bacteria and generating health readouts, but their analytical accuracy remains uncertain. A new study shows that... Read more
WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
Tuberculosis (TB) remains one of the world’s leading infectious disease killers, yet millions of cases go undiagnosed or are detected too late. Barriers such as reliance on sputum samples, limited laboratory... Read more
Pathology
view channel
Biopsy-Based Gene Test Predicts Recurrence Risk in Lung Adenocarcinoma
Lung cancer is the leading cause of cancer death, killing more people in the United States than breast, prostate, and colon cancers combined. In lung adenocarcinoma (LUAD), tumors that invade nearby blood... Read more
AI-Powered Tool to Transform Dermatopathology Workflow
Skin cancer accounts for the largest number of cancer diagnoses in the United States, placing sustained pressure on pathology services. Diagnostic interpretation can be variable for challenging melanocytic... Read more
Technology
view channel
Online Tool Supports Family Screening for Inherited Cancer Risk
Genetic test results in oncology often have implications for relatives who may share inherited cancer risk. Many health systems lack structured processes to help patients alert family members, limiting... Read more
Portable Breath Sensor Detects Pneumonia Biomarkers in Minutes
Pneumonia is commonly confirmed with chest X-rays or laboratory assays that can take hours, delaying clinical decisions in acute and outpatient settings. Breath-based diagnostics promise faster answers... Read more
Industry
view channel
Integrated DNA Technologies Expands into Clinical Diagnostics
Integrated DNA Technologies (IDT; Coralville, Iowa, USA) has announced the launch of Archer FUSIONPlex-HT Dx and VARIANTPlex-HT Dx. This launch marks the company’s first in vitro diagnostic (IVD) offerings... Read more
